EI
MNPR icon

EAM Investors’s Monopar Therapeutics MNPR Stock Holding History

EAM Investors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,225
Closed -$341K – 349
2026
Q1 		$341K Sell
6,225
-5,148
-45% -$311K 0.04% 272
2025
Q4 		$743K Sell
11,373
-3,256
-22% -$266K 0.08% 235
2025
Q3 		$1.19M Buy
+14,629
New +$654K 0.14% 181

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

EAM Investors's MNPR Position: Q2 2026 in Review

EAM Investors sold out of Monopar Therapeutics (MNPR) in Q2 2026, closing a stake of 6,225 shares — an estimated $341K sold.

EAM Investors first reported a position in MNPR in Q3 2025 and held it in 3 quarters. The position peaked at $1.19M in Q3 2025. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • EAM Investors reported no remaining Monopar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 6,225 Monopar Therapeutics shares in Q2 2026, an estimated $341K.
  • EAM Investors first reported a position in Monopar Therapeutics in Q3 2025 and held it in 3 quarters.
  • EAM Investors's Monopar Therapeutics position peaked at $1.19M in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.